\BOOKMARK [1][-]{section.1}{Introduction}{}% 1
\BOOKMARK [1][-]{section.2}{Results}{}% 2
\BOOKMARK [2][-]{subsection.2.1}{extTADA pipeline}{section.2}% 3
\BOOKMARK [2][-]{subsection.2.2}{Test extTADA on simulated data. }{section.2}% 4
\BOOKMARK [3][-]{subsubsection.2.2.1}{Test extTADA for only CC data}{subsection.2.2}% 5
\BOOKMARK [3][-]{subsubsection.2.2.2}{Evaluate the performance on integrated DN and CC data}{subsection.2.2}% 6
\BOOKMARK [2][-]{subsection.2.3}{Schizophrenia data sets}{section.2}% 7
\BOOKMARK [3][-]{subsubsection.2.3.1}{Extract data sets to analyze integratively}{subsection.2.3}% 8
\BOOKMARK [3][-]{subsubsection.2.3.2}{Integrated analysis of de novo mutations and case-control variants}{subsection.2.3}% 9
\BOOKMARK [3][-]{subsubsection.2.3.3}{Test enrichment of SCZ-risk genes in gene sets}{subsection.2.3}% 10
\BOOKMARK [3][-]{subsubsection.2.3.4}{Identify number of risk genes for SCZ studies with different sample sizes}{subsection.2.3}% 11
\BOOKMARK [3][-]{subsubsection.2.3.5}{Test for single classes of SCZ data}{subsection.2.3}% 12
\BOOKMARK [3][-]{subsubsection.2.3.6}{Test genetic architecture of SCZ using both InExAC and NoExAC variants}{subsection.2.3}% 13
\BOOKMARK [3][-]{subsubsection.2.3.7}{Test the influence of mutation rates to the analyzing results of SCZ}{subsection.2.3}% 14
\BOOKMARK [2][-]{subsection.2.4}{Estimate genetic parameters of other neurodevelopmental diseases using extTADA}{section.2}% 15
\BOOKMARK [2][-]{subsection.2.5}{Novel risk genes in ID and DD diseases.}{section.2}% 16
\BOOKMARK [1][-]{section.3}{Discussion}{}% 17
\BOOKMARK [1][-]{section.4}{Data and methods}{}% 18
\BOOKMARK [2][-]{subsection.4.1}{Data}{section.4}% 19
\BOOKMARK [3][-]{subsubsection.4.1.1}{Simulation data}{subsection.4.1}% 20
\BOOKMARK [3][-]{subsubsection.4.1.2}{Variant data of SCZ, ID, DD, EPI and ASD}{subsection.4.1}% 21
\BOOKMARK [3][-]{subsubsection.4.1.3}{Gene sets}{subsection.4.1}% 22
\BOOKMARK [2][-]{subsection.4.2}{Methods}{section.4}% 23
\BOOKMARK [3][-]{subsubsection.4.2.1}{extTADA pipeline: analyze de novo, transmission and case-control data}{subsection.4.2}% 24
\BOOKMARK [3][-]{subsubsection.4.2.2}{Use simulation data to test model}{subsection.4.2}% 25
\BOOKMARK [3][-]{subsubsection.4.2.3}{Calculate mutation rates}{subsection.4.2}% 26
\BOOKMARK [3][-]{subsubsection.4.2.4}{Analyze SCZ data}{subsection.4.2}% 27
\BOOKMARK [3][-]{subsubsection.4.2.5}{Use extTADA to predict genetic parameters of other neurodevelopmental diseases}{subsection.4.2}% 28
\BOOKMARK [3][-]{subsubsection.4.2.6}{Infer parameters using MCMC results}{subsection.4.2}% 29
\BOOKMARK [1][-]{section.5}{Acknowledgements}{}% 30
\BOOKMARK [1][-]{section.6}{Supplementary information}{}% 31
\BOOKMARK [2][-]{subsection.6.1}{Sup Table}{section.6}% 32
\BOOKMARK [2][-]{subsection.6.2}{Sup Figure}{section.6}% 33
\BOOKMARK [2][-]{subsection.6.3}{Sup Information}{section.6}% 34
